Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate

Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol. 2003; 22:814A.


© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.